Surging Into Intel<br />By Rev Shark<br />RealMoney.com Contributor<br />7/13/2010 8:16 AM EDT <br /><br />If winning isn't everything, why do they keep score? <br />-- Vince Lombardi<br /><br />We are set to open strongly this morning as optimism about earnings season is building. The first few earnings reports from Alcoa (AA) , Novellus (NVLS) and CSX Corp. (CSX) were solid, but we also have a boost from BP (BP) , which made some progress with the Gulf of Mexico oil leak. Banks led the action overseas and mining and commodities are bouncing back after poor action yesterday. A downgrade of sovereign debt of Portugal is having no immediate impact. <br /><br />Following this upbeat open, the market's focus is going to very quickly shift to the key report due out after the close -- Intel (INTC) . Intel's earnings report has often marked a turning point in the market, so it is going to be very carefully scrutinized. <br /><br />The last two quarters, Intel gapped up on very good earnings but reversed quickly and went straight down for weeks. A big Intel report back in the second quarter of 2009 helped to propel the market to an exceptional rally during the month of July after a near breakdown. <br /><br />The big difference in the July 2009 quarter from the last two quarters was that the market was not trending up or near a recent high. When the market is hitting short-term highs, there is much greater risk that Intel's report will be a turning point. <br /><br />With the gap-up open this morning, the market is looking at its sixth successive day of gains, adding some danger of a "sell the news" reaction to earnings. We also are moving closer to that significant resistance around 1100 of the S&P 500, but at the moment this is looking like some of that good old-fashioned "V"-ish action that drove this market from March 2009 to April 2010. <br /><br />It is extremely easy to find fault with the bounce we are presently enjoying. It has come on low volume and poor breadth, and technical overhead is looming. On the other hand, the market has often continued to rally without pause during the past year when similar conditions existed. We are at that point now where bears and underinvested bulls become extremely anxious as the market continues upward without providing good entry points. The longer it continues, the greater the underlying buying pressures build. <br /><br />The opening strength is fading just a little as I write, and I wouldn't be surprised to see us calm down more as we await Intel. Shorting on the INTC report was a winning trade the last two quarters, and many market players will be considering that as the numbers hit tonight. <br /><br />We are at a very tricky juncture right now, so buckle up and adjust your trading helmet -- the action is going to heat up. <br />-----------------------------------<br />Briefing.com vahendusel:<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: AA +3.5%, BRKS +3.4% (light volume), NVLS +2.0%, CSX +1.4%, CVX +1.2%. <br /><br />Select financial related names showing strength: C +2.2%, HBAN +2.0%, HBC +1.9%, LYG +1.6%, SNV +1.5%, ING +1.2%, RF +1.1%... WFC +1.1%, JPM +1.1%, GS +0.8% and MS +1.2% (initiated with Positives at Susquehanna), . <br /><br />Select metals/mining related stocks trading higher boosted by AA results: CENX +4.3%, TCK +2.2%, BBL +2.1%, RTP +2.1%, ACH +2.1%, AKS +1.6%, FCX +1.5%, X +1.4%, BHP +1.3%, MT +1.0%. <br /><br />Select oil/gas related names showing strength: ESV +2.4% (Greenlight Capital discloses 5.2% stake in 13G filing), BP +2.3% (announces capping stack was installed on M252 well), APC +1.8%, CHK +1.7%, TOT +1.2%. <br /><br />Select mortgage/insurer related names getting boost: RDN +9.0%, MBI +6.6% (Fairholme Funds files 13-g announcing an 11.1% stake ), PMI +3.6%, ABK +3.1%, GNW +2.4%. <br /><br />Other news: VVUS +30.5% (FDA releases VVUS briefing documents), RZ +15.7% (announces agreement and substantial payment of Thermo No. 1 debt obligations), OREX +10.6% and ARNA +8.2% (up in sympathy with VVUS), THLD +9.8% (TH-302 enhances efficacy of two antiangiogenic agents and, in a separate study, demonstrates selectivity in pancreatic cancer by targeting a distinct tumor compartment from that of Gemcitabine), S +3.8% (still checking), ERIC +3.3% (checking for anything specific), FBC +3.2% (successfully regains compliance with NYSE minimum share price listing requirement), GSK +1.3% (FDA Panel to meet on GSK's Avandia today and tomorrow; may cause volatility in stock as headlines cross), RIMM +1.3% (announces TSX approval for common share repurchase program), BIDU +1.1% (Cramer makes positive comments on MadMoney).<br /><br />Analyst comments: UN +2.4% (upgraded to Buy from Neutral at Goldman; added to Conviction Buy list), BTI +2.1% (upgraded to Buy from Neutral at Goldman). <br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: CVLT -23.1% (also downgraded to Hold at Stifel Nicolaus), AMED -14.3% (also downgraded to Sector Perform from Outperform at RBC Capital), ID -4.1% , INFY -4.0%. <br /><br />Select healthcare facility related names trading lower following AMED guidance: AFAM -6.0%, LHCG -5.7% . <br /><br />Other news: REVU -9.2% (still checking), BMTI -7.0% (announces 5 mln common stock offering), SQNM -2.0% (still checking), GGP -1.5% (files plan of reorganization and disclosure statement), . <br /><br />Analyst comments: ATPG -6.8% (downgraded to Underweight from Neutral at JP Morgan), URBN -2.6% (downgraded to Neutral from Buy at Goldman), ANN -1.6% (downgraded to Neutral from Buy at Goldman).